Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Victoza Archives
Print | Email | Share | Comments (0)

Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs


Nov 5, 2012

Eli Lilly & Co

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.

According to Lilly, dulaglutide, a GLP-1 analog, worked better to reduce A1c levels than metformin, Merck & Co.'s Januvia (sitagliptin), and Bristol-Meyers Squibb Co.'s Byetta (exenatide). A GLP-1 analog works by stimulating the production of insulin.

Although the company reported that the three studies showed that 1.5mg injections of dulaglutide worked better at lowering A1c levels than the other three drugs, it did not report specific numbers. Also, Lilly did not test the drug against Bristol-Meyers Squibb's Bydureon or Novo Nordisk's Victoza, two recently introduced GLP-1 analogs.

Dulaglutide's once-a-week dosing requirement could give it a marketing edge. Each of the drugs it was compared with must be taken daily: Metformin orally twice daily just before or with meals; Byetta injected twice daily before meals; Januvia orally once daily.

Bydureon is injected once weekly, while Victoza is injected once daily.

The success of the Phase III study means that Lilly will seek FDA approval to begin marketing the drug in the United States next year.


Categories: Bristol-Meyers Squibb, Byetta, Dulaglutide, Eli Lilly & Co, Exenatide, FDA, GLP-1 analog, Injections, Januvia, Merck & Co, Metformin, Novo Nordisk, Sitagliptin, Study, Victoza



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Nov 5, 2012

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.